Enobia has raised more than $145m from universities seed fund T2C2 (Technology, Transfer, Commercialisation, Capital) and venture capital firms.
Alexion Pharmaceuticals, a Nasdaq-listed drugs company, has agreed to buy peer Enobia Pharma for up to $1.1bn in cash from its venture consortium that includes universities fund T2C2.
Canada-based Enobia developes therapeutics for serious bone disorders and the deal includes a $610m initial payment and up to $470m in performance fees. Enobia has raised more than $145m from universities seed fund T2C2 (Technology, Transfer, Commercialisation, Capital) and venture capital firms CTI Life Sciences Fund, Desjardins Venture Capital, Kirchner Investment Management…
